Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - dopamine hydrochloride 1600 mg/ml - solution for infusion - 1600 mg/ml - active: dopamine hydrochloride 1600 mg/ml excipient: glucose monohydrate hydrochloric acid sodium bisulfite water for injection

Ísrael - enska - Ministry of Health

raz pharmaceutics ltd, israel - dopamine hydrochloride - concentrate for solution for infusion - dopamine hydrochloride 40 mg / 1 ml - dopamine - dopamine hydrochloride s.a.l.f. is used for the treatment of states of shock of different nature:- post myocardial infarction cardiogenic shock, a shock caused by a heart attack,- surgical shock, caused by a surgical operation,- hypovolemic or haemorrhagic shock, caused by a decrease in blood volume due to a hemorrhage,a shock is characterized by a sharp decrease in blood pressure in response to a reduced blood flow in the organism.

Bandaríkin - enska - NLM (National Library of Medicine)

hospira, inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride 0.8 mg in 1 ml - dopamine hydrochloride in dextrose injection is indicated to improve hemodynamic status in patients in distributive shock, or shock due to reduced cardiac output. dopamine is contraindicated in patients with pheochromocytoma. risk summary there are no human data with dopamine use in pregnant women. there are risks to the mother and fetus from hypotension associated with shock, which can be fatal if left untreated (see clinical considerations ). in animal reproduction studies, adverse developmental outcomes were observed with intravenous dopamine hcl administration in pregnant rats during organogenesis at dosages, on a mcg/m2 basis, of one-third the human starting dosage of 2 mcg/kg/minute (90 mcg/m2 /minute). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies carry some risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the background risk of major birth defects and miscarriage in clinically recognized pregna

Bandaríkin - enska - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride 40 mg in 1 ml - dopamine hydrochloride, usp is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hydrochloride, usp are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hydrochloride, usp, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hydrochloride, usp. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be mo

Bandaríkin - enska - NLM (National Library of Medicine)

general injectables & vaccines, inc - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride 40 mg in 1 ml - dopamine hcl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hcl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hcl, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hcl. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. nevertheless, the physician should also observe the

Bandaríkin - enska - NLM (National Library of Medicine)

hospira, inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride 40 mg in 1 ml - dopamine hcl injection is indicated to improve hemodynamic status in patients in distributive shock or shock due to reduced cardiac output. dopamine is contraindicated in patients with pheochromocytoma. risk summary there are no human data with dopamine use in pregnant women. there are risks to the mother and fetus from hypotension associated with shock, which can be fatal if left untreated (see clinical considerations ). in animal reproduction studies, adverse developmental outcomes were observed with intravenous dopamine hcl administration in pregnant rats during organogenesis at doses, on a mcg/m2 basis, of one‑third the human starting dose of 2 mcg/kg/minute (90 mcg/m2 /minute). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies carry some risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2‑4% and 15‑20%,

Malta - enska - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - dopamine hydrochloride - concentrate for solution for infusion - dopamine hydrochloride 40 mg/ml - cardiac therapy

Írland - enska - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - dopamine hydrochloride - concentrate for solution for infusion - 40 milligram(s)/millilitre - adrenergic and dopaminergic agents; dopamine

Írland - enska - HPRA (Health Products Regulatory Authority)

hospira uk limited - dopamine hydrochloride - concentrate for soln for inf - 40 mg/ml - adrenergic and dopaminergic agents

Bandaríkin - enska - NLM (National Library of Medicine)

baxter healthcare corporation - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride 80 mg in 100 ml - dopamine hydrochloride is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarctions, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in congestive failure. where appropriate, restoration of blood volume with a suitable plasma expander or whole blood should be instituted or completed prior to administration of dopamine hydrochloride. patients most likely to respond adequately to dopamine hydrochloride are those in whom physiological parameters, such as urine flow, myocardial function and blood pressure have not undergone profound deterioration. reports indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with volume correction and dopamine hydrochloride, the better the prognosis. urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. nevertheless, the physician should also observe the